OmniAb (OABI) Expected to Announce Quarterly Earnings on Tuesday

OmniAb (NASDAQ:OABI) will likely be issuing its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $5.6440 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

OmniAb (NASDAQ:OABI) last posted its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). OmniAb had a negative return on equity of 22.79% and a negative net margin of 275.83%.The business had revenue of $3.90 million during the quarter, compared to analyst estimates of $5.33 million. On average, analysts expect OmniAb to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OmniAb Price Performance

OABI opened at $1.55 on Monday. OmniAb has a fifty-two week low of $1.22 and a fifty-two week high of $4.87. The firm has a market capitalization of $223.14 million, a PE ratio of -2.58 and a beta of 0.15. The company’s 50-day moving average is $1.62 and its 200 day moving average is $1.71.

Institutional Investors Weigh In On OmniAb

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in shares of OmniAb during the 1st quarter valued at approximately $25,000. Osaic Holdings Inc. grew its position in shares of OmniAb by 214.4% during the 2nd quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock valued at $25,000 after acquiring an additional 9,716 shares during the period. Cerity Partners LLC grew its position in shares of OmniAb by 111.5% during the 2nd quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock valued at $39,000 after acquiring an additional 11,919 shares during the period. Corient Private Wealth LLC bought a new position in shares of OmniAb during the 2nd quarter valued at approximately $53,000. Finally, The Manufacturers Life Insurance Company grew its position in shares of OmniAb by 20.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,809 shares of the company’s stock valued at $78,000 after acquiring an additional 7,624 shares during the period. Hedge funds and other institutional investors own 72.08% of the company’s stock.

Wall Street Analyst Weigh In

OABI has been the topic of a number of analyst reports. Royal Bank Of Canada lowered their target price on shares of OmniAb from $4.00 to $3.00 and set an “outperform” rating on the stock in a report on Thursday, August 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of OmniAb in a research note on Tuesday, October 14th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $6.67.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.